Abstract: The invention relates to a system for characterising the sleep of an individual, the characterisation system comprising: a measuring device for measuring a brain activity signal representing the brain waves; a central electronic unit for identifying, in a range of frequencies of between 9 and 16 Hz, a smaller range of sleep spindles of the individual, the smaller range of sleep spindles comprising the brain wave frequencies of the sleeping individual, having an amplitude higher than 15 ?V and a duration of between 0.5 seconds and 2 seconds, and comparing, with a threshold, at least one parameter of the brain activity signal of the awake individual in the range of frequencies corresponding to the smaller range of sleep spindles; and a communication interface connected to the central unit and used to emit a warning signal perceptible by the individual when the parameter of the brain activity signal in the range of frequencies corresponding to the smaller range of sleep spindles exceeds the threshold.

Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

Abstract: The invention relates to a system for characterising the sleep of an individual, the characterisation system comprising: a measuring device for measuring a brain activity signal representing the brain waves; a central electronic unit for identifying, in a range of frequencies of between 9 and 16 Hz, a smaller range of sleep spindles of the individual, the smaller range of sleep spindles comprising the brain wave frequencies of the sleeping individual, having an amplitude higher than 15 ?V and a duration of between 0.5 seconds and 2 seconds, and comparing, with a threshold, at least one parameter of the brain activity signal of the awake individual in the range of frequencies corresponding to the smaller range of sleep spindles; and a communication interface connected to the central unit and used to emit a warning signal perceptible by the individual when the parameter of the brain activity signal in the range of frequencies corresponding to the smaller range of sleep spindles exceeds the threshold.

Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologs thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologs thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

Abstract: The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.